| Database ID | Agent | Target | Cancer Type | Detail |
| DB00241 | olaparib | Poly [ADPribose] polymerase1 | prostate cancer | view |
| DB00242 | niraparib | PARP1 and PARP2 | advanced solid tumors | view |
| DB00243 | ODM201 | androgen receptor (AR) | prostate cancer | view |
| DB00244 | temsirolimus | Serine/threonineprotein kinase mTOR | prostate cancer | view |
| DB00245 | ridaforolimus | Serine/threonineprotein kinase mTOR | prostate cancer | view |
| DB00246 | ridaforolimus | Serine/threonineprotein kinase mTOR | prostate cancer | view |
| DB00247 | everolimus | Serine/threonineprotein kinase mTOR | prostate cancer | view |
| DB00248 | everolimus | Serine/threonineprotein kinase mTOR | prostate cancer | view |
| DB00249 | everolimus | Serine/threonineprotein kinase mTOR | prostate cancer | view |
| DB00250 | temsirolimus | Serine/threonineprotein kinase mTOR | prostate cancer | view |
| DB00251 | temsirolimus | Serine/threonineprotein kinase mTOR | advanced solid tumors | view |
| DB00252 | temsirolimus | Serine/threonineprotein kinase mTOR | prostate cancer | view |
| DB00253 | AZD0530 | Protooncogene tyrosineprotein kinase SRC, Abl | prostate cancer | view |
| DB00254 | cetuximab | Epidermal growth factor receptor | head and neck cancer | view |
| DB00255 | cetuximab | Epidermal growth factor receptor | head and neck cancer | view |